Latest Breaking News On - Bryostatin trial - Page 1 : comparemela.com

Synaptogenix trial - extremely important outcome for Alzheimer s

Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.

United statesAlan tuchmanDaniel alkonNational cancer instituteNational institute on agingSynaptogenix incAdvanced alzheimerPatients show safePersistent benefitBryostatin trialMild cognitive impairmentSevere cohortNational instituteClinical developmentDrug deliveryAtient centricity

Synaptogenix (SNPX) Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1

Synaptogenix (SNPX) Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlan tuchmanDaniel alkonDrug administrationNational institute on agingNational cancer instituteSynaptogenix incExchange commissionPatients show safePersistent benefitBryostatin trialSevere cohortChief executive officerMild cognitive impairmentChief scientific officerModerate cohort